News

Gut linked to drug response

Saturday 19 November 2016
Country
United Kingdom

Immunotherapy for treating metastasised melanoma works better when there is a diversity of bacteria in the gut, according to a study by researchers at the University of Texas MD Anderson Cancer Center in the US.

Transcription factor guides mitosis

Saturday 19 November 2016
Country
France

As embryonic stem cells divide, they are able to express the same genes as the original cell despite all the possibilities of mutation. Now, scientists from the Institut Pasteur have identified a transcription factor, Esrrb (estrogen related receptor beta), that makes this possible.

Damaged neurons repaired

Saturday 19 November 2016
Country
Germany

German scientists have successfully replaced damaged nerve cells in the brains of mice fueling hope that the wreckage caused by Alzheimer’s or Parkinson’s disease might be repaired in the future. Normally, nerve cell losses in the brain cannot be restored.

Cell Medica goes allogeneic

Friday 11 November 2016
Country
United Kingdom

Cell Medica Ltd has expanded an existing partnership with the Baylor College of Medicine in Texas, US to develop allogeneic cell therapies based on engineered immune cells generated from healthy donors. The cells are invariant natural killer T (NKT) cells.

CureVac secures new investors

Friday 11 November 2016
Country
Germany

CureVac AG, which is developing vaccines based on messenger RNA technology, has raised $29.5 million from two new German investors to advance its portfolio. This follows a private share placement in 2015 that raised $110 million.

Evotec reports sharply higher results

Thursday 10 November 2016
Country
Germany

Evotec AG reported a 37% increase in revenue to €120.6 million for the first nine months as its drug discovery business on behalf of Sanofi SA moved into high gear and revenue from other long-term partners increased.

Nicox gives update on glaucoma drug

Thursday 10 November 2016
Country
France

France-based Nicox SA said it anticipates a regulatory review of its glaucoma drug latanoprostene bunod to take place soon, and if the result is positive, the treatment could be on the US market by mid-2017.

AstraZeneca tightens focus

Thursday 10 November 2016
Country
United Kingdom

AstraZeneca Plc is accelerating development of its oncology portfolio and tightening its therapeutic focus with an eye to returning to growth by 2018, or possibly earlier. The company’s third quarter results, released on 10 November, showed group revenue down by 4% to $5.7 billion, but new therapies in oncology and diabetes posted stronger sales.

Syncona merger targets UK science

Tuesday 8 November 2016
Country
United Kingdom

Syncona LLP, the evergreen investment fund of the Wellcome Trust, is poised to increase its investment in UK life science through a merger with the Guernsey-based investment fund BACIT Ltd. The new group will keep the Syncona name and be listed on the London Stock Exchange.

MorphoSys confirms guidance

Monday 7 November 2016
Country
Germany

MorphoSys AG has confirmed that its revenue this year is expected to be in a range of €47 million to €52 million and that its operating loss will amount to between €58 million and €68 million. The forecast was issued with the publication of the company’s third and nine-month results.